PMID- 12698536
OWN - NLM
STAT- MEDLINE
DCOM- 20030507
LR  - 20141120
IS  - 0008-7335 (Print)
IS  - 0008-7335 (Linking)
VI  - 142
IP  - 2
DP  - 2003 Feb
TI  - [Detection of HER-2/neu in breast carcinoma].
PG  - 93-8
AB  - BACKGROUND: HER-2/neu protein overexpression has been shown to be an 
      independently adverse prognostic and predictive factor in patients with breast 
      cancer. Recently, HER-2/neu overexpression has gained therapeutic implications: 
      It has been shown that in patients with breast cancer the use of 
      trastuzumab/Herceptin TM, the recombinant humanized monoclonal antibody directed 
      against extracellular domain of HER-2/neu molecule, can block the HER-2/neu 
      protein activation and bring about a clinical remission. Following these 
      developments, demand for pathologists to evaluating properly HER-2/neu in breast 
      cancer specimens has been rapidly increasing. METHODS AND RESULTS: In our series 
      of 449 cases of breast cancer, HER-2/neu protein and gene were examined by means 
      of immunohistochemistry and fluorescence in situ hybridization respectively. 
      Results of HER-2/neu study were compared with the hormonal status, cancer grade 
      and proliferation activity as assessed using immunohistochemistry with MIB1 
      antibody. All seven cases of breast cancer with strong overexpression of 
      HER-2/neu (score 3+) manifested a gene amplification. In contrast, among 11 cases 
      of breast cancers with mild HER-2/neu overexpression (score 2+), the gene 
      amplification was demonstrated in 5 cases only (45%). CONCLUSIONS: 
      Immunohistochemical assessment and fluorescence in situ hybridization (FISH) are 
      complementary methods for detection of HER-2/neu status in breast cancer. While 
      immunohistochemistry is an excellent screening method, FISH should be used for 
      the confirmation of positive results before the Herceptin treatment.
FAU - Skalova, A
AU  - Skalova A
AD  - Patologicko-anatomicky ustav LF UK, Biopticka laborator s.r.o., Plzen. 
      skalova@fnplzen.cz
FAU - Vanecek, T
AU  - Vanecek T
FAU - Losan, F
AU  - Losan F
FAU - Papoutsidesova
AU  - Papoutsidesova
FAU - Finek, J
AU  - Finek J
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Prukaz HER-2/neu v karcinomu mlecne zlazy.
PL  - Czech Republic
TA  - Cas Lek Cesk
JT  - Casopis lekaru ceskych
JID - 0004743
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*chemistry/genetics/pathology
MH  - Female
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*analysis
MH  - Receptors, Estrogen/analysis
MH  - Receptors, Progesterone/analysis
EDAT- 2003/04/18 05:00
MHDA- 2003/05/08 05:00
CRDT- 2003/04/18 05:00
PHST- 2003/04/18 05:00 [pubmed]
PHST- 2003/05/08 05:00 [medline]
PHST- 2003/04/18 05:00 [entrez]
PST - ppublish
SO  - Cas Lek Cesk. 2003 Feb;142(2):93-8.